Colorectal Cancer Diagnostics Market Report: 2026-2035

Executive Overview: Colorectal Cancer Diagnostics Market

The global colorectal cancer (CRC) diagnostics market was valued at USD 14.50 billion in 2025 and is projected to reach USD 15.80 billion in 2026, advancing at a CAGR of 8.0% to attain USD 31.30 billion by 2035. This growth is underpinned by an expanding screening-eligible population, policy-driven access mandates, and technological integration across the diagnostic pathway. Our proprietary analysis indicates that the market stood at USD 10.20 billion in 2022, reflecting substantial commercial momentum built over the historic period as non-invasive testing adoption and AI-assisted endoscopy integration widened the revenue base.

The market combines an established revenue base in endoscopy and pathology with a widening non-invasive testing layer spanning stool-based and blood-based approaches. This evolution expands access to screening while retaining downstream procedural and tissue-confirmation pathways that support diagnostic spending across the patient journey. The interplay between screening accessibility, reimbursement frameworks, and clinical adoption will determine the pace of forecast realization.

Key Market Drivers & Restraints

Demand is shaped by the interaction of a growing screening-eligible population, policy-led access expansion, and technology that adds software and service revenue to conventional diagnostic workflows.

Key Drivers

• Rising Global CRC Disease Burden: More than 2.0 million new colorectal cancer cases were recorded globally in 2024, with Asia accounting for 52.2% of the total incidence burden (International Agency for Research on Cancer / WHO Global Cancer Observatory, GLOBOCAN 2024). A larger and younger at-risk population expands addressable demand for diagnostic testing across all modalities on a sustained multi-year basis.
• Government-Mandated Expansion of CRC Screening Eligibility: In May 2021, the U.S. Preventive Services Task Force lowered the recommended CRC screening age from 50 to 45, adding approximately 19 million newly eligible U.S. adults to the insured-screening population. Mandated insurance coverage for this cohort directly increases reimbursed test orders and colonoscopy volumes.
• Integration of AI-Assisted Computer-Aided Detection (CADe) Platforms: Regulatory-cleared CADe systems, including GI Genius (Medtronic) and EndoAid (Olympus), are deployed as clinical decision support tools within existing endoscopy suites. These systems generate recurring software licensing and service contract revenue above the traditional hardware replacement cycle.

Key Restraints

• Persistent Adherence Gap: Only 61% of U.S. adults aged 45-75 were up-to-date with colorectal cancer screening in 2022, well below the Healthy People 2030 target of 74.4% (Centers for Disease Control and Prevention). Unrealized demand within the eligible population limits actual test volumes relative to the theoretical addressable market.
• Insurance and Income-Related Access Disparities: Only 23.8% of uninsured U.S. adults under age 65 were up-to-date with colorectal cancer screening in 2023 (CDC). Cost and coverage barriers constrain test volumes among commercially uninsured segments.
• Incomplete Diagnostic Pathway Requirements: FDA-cleared blood-based CRC screening tests, including Shield (approved July 2024), require confirmatory colonoscopy for all positive results due to limited sensitivity for advanced precancerous lesions. This confirmation requirement reduces the practical convenience advantage of blood-based tests, limiting standalone market-expansion potential.

Segment Analysis

By Test Type

The market is segmented into endoscopy (colonoscopy and sigmoidoscopy), laboratory tests (stool-based tests, blood-based tests, and molecular diagnostics), imaging, and biopsy. Endoscopy remains the dominant segment, accounting for the largest revenue share in 2025, driven by its role as the gold standard for CRC diagnosis and the growing adoption of AI-assisted CADe systems. Laboratory tests, particularly stool-based and blood-based non-invasive tests, represent the fastest-growing segment, fueled by rising demand for convenient, at-home screening options.

By End Use

Hospitals and clinics held the largest market share, at approximately 53% in 2025, due to high patient volumes and the concentration of advanced diagnostic technologies. Clinical laboratories are projected to witness the fastest growth, driven by increasing outsourcing of diagnostic testing and the expansion of molecular diagnostics capabilities.

Regional Outlook

North America dominated the market with a share of approximately 34% in 2025, attributed to well-established screening programs, high healthcare expenditure, and the early adoption of advanced diagnostic technologies. The U.S. remains the largest contributor, supported by the USPSTF screening-age expansion and favorable reimbursement policies.

Asia Pacific is expected to register the highest CAGR of 8.5% over the forecast period, driven by a large and aging population, increasing government initiatives for cancer screening, and improving healthcare infrastructure. China and Japan are key markets, with rising awareness and investment in early detection.

Europe holds a significant market share, supported by organized screening programs and the presence of major diagnostic companies. Latin America and the Middle East & Africa are anticipated to experience steady growth, albeit from a smaller base, as healthcare access improves and governments launch awareness campaigns.

Competitive Landscape

The market is moderately consolidated, with the top five players—Exact Sciences, Olympus Corporation, Boston Scientific, Siemens Healthineers, and Roche Diagnostics—collectively holding a 45.2% market share in 2025. Exact Sciences led with over 16.8% market share, driven by its Cologuard stool-based test and strong direct-to-consumer marketing. Strategic initiatives focus on product innovation, partnerships, and geographic expansion.

Recent Industry Developments:

• July 2024: FDA approval of Shield (Guardant Health) blood-based CRC screening test.
• 2023: Medtronic received FDA clearance for GI Genius CADe system.
• 2022: Exact Sciences launched Cologuard Plus with improved sensitivity.

Value Chain Analysis

The value chain spans research and development, manufacturing, distribution, and end-user delivery. Key participants include diagnostic test manufacturers, endoscopy equipment suppliers, software developers for AI-assisted detection, and service providers such as laboratories and hospitals. The integration of digital health solutions and remote monitoring is creating new service revenue streams.

Strategic White-Space Analysis

Significant opportunities exist in the development of blood-based tests with higher sensitivity for precancerous lesions, integration of multi-cancer early detection (MCED) tests, and expansion into emerging markets with large unmet screening needs. Additionally, the adoption of AI and machine learning for image analysis and risk stratification presents a high-growth avenue for stakeholders.

Import/Export & Supplier Dynamics

Trade data for colorectal cancer diagnostics is not uniformly tracked at the product level; however, the supply chain is globalized. Major manufacturing hubs include the U.S., Germany, Japan, and China. Key component suppliers include those providing antibodies, probes, and endoscopic instruments. Tariff and trade policies can impact pricing and availability, particularly for cross-border flows of diagnostic equipment. The COVID-19 pandemic highlighted the need for supply chain resilience, prompting companies to diversify sourcing and increase inventory buffers.